Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion

Journal of Neuroscience Research

Volumn 83, Issue 2, 2006, Pages 285-291

  Cho, Kyung Ok ^a   La, Hyen O ^a   Cho, Young Jin ^a   Sung, Ki Wug ^a   Kim, Seong Y ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Chronic cerebral hypoperfusion; Microglial activation; Minocycline; MMP 2; White matter damage

Indexed keywords

GELATINASE A; MAJOR BASIC PROTEIN; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN PERFUSION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; WHITE MATTER;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; BRAIN DAMAGE, CHRONIC; CORPUS CALLOSUM; DEMENTIA, VASCULAR; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MINOCYCLINE; MYELIN BASIC PROTEINS; RATS; RATS, WISTAR; VISUAL PATHWAYS;

EID: 31844454079     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.20727     Document Type: Article

References (23)

1. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H. 1998. Blood-brain barrier dysfunction in Binswanger's disease: an immunohistochemical study. Acta Neuropathol (Berl) 95:78-84.
2. Akiguchi I, Tomimoto H, Wakita H, Kawamoto Y, Matsuo A, Ohnishi K, Watanabe T, Budka H. 2004. Topographical and cytopathological lesion analysis of the white matter in Binswanger's disease brains. Acta Neuropathol (Berl) 107:563-570.
3. Brundula V, Rewcastle NG, Metz LM, Bernard CC, Yong VW. 2002. Targeting leukocyte MMPs and transmigration Minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308.
4. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. 1995. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201:223-226.
5. Domercq M, Matute C. 2004. Neuroprotection by tetracyclines. Trends Pharmacol Sci 25:609-612.
6. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DLG, Luecke S, Phebus LA, Bymaster FP, Paul SM. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:14669-14674.
7. Ihara M, Tomimoto H, Kinoshita M, Oh J, Noda M, Wakita H, Akiguchi I, Shibasaki H. 2001. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab 21:828-834.
8. Klüver H, Barrera E. 1953. A method for the combined staining of cells and fibers in the nervous system. J Neuropathol Exp Neurol 12:400-403.
9. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A. 2003. Long term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 30:266-272.
10. Paxinos G, Watson C. 1997. The rat brain in stereotaxic coordinates. 3rd edition. Orlando: Academic Press.
11. Popovic N, Schubart A, Goetz BD, Zhang S-C, Linington C, Duncan ID. 2002. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51:215-223.
12. Power C, Henry S, Del Bigio MR, Larsen PH, Cobett D, Imai Y, Yong VW, Peeling J. 2003. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 53:731-742.
13. Rosenberg GA, Kornfeld M, Estrada E, Kelly RO, Liotta LA, Stetler-Stevenson WG. 1992. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576:203-207.
14. Rosenberg GA, Sullivan N, Esiri MM. 2001. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 32:1162-1168.
15. Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG. 2004. Minocycline inhibits neuronal death and glial activation induced by β-amyloid peptide in rat hippocampus. Glia 48:85-90.
16. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W. 2004. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24:2182-2190.
17. Tanaka K, Ogawa N, Asanuma M, Kondo Y, Nomura M. 1996. Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion. Brain Res 729:55-65.
18. Wakita H, Tomimoto H, Akiguchi I, Kimura J. 1997. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol (Berl) 87:484-492.
19. Wakita H, Tomimoto H, Akiguchi I, Kimura J. 1998. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain Res 792:105-113.
20. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi D, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771.
21. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. 1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95:15769-15774.
22. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. 1999. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496-13500.
23. Zemke D, Majid A. 2004. The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 27:293-298.